PURE Bioscience, Inc.
PURE
$0.0688
$0.013825.09%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -22.99% | -21.26% | 8.35% | -17.88% | 53.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.99% | -21.26% | 8.35% | -17.88% | 53.29% |
| Cost of Revenue | -17.50% | -29.18% | -13.27% | -25.50% | 30.84% |
| Gross Profit | -26.47% | -14.33% | 31.63% | -10.15% | 71.98% |
| SG&A Expenses | -17.89% | -11.98% | 0.10% | -9.75% | -7.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.45% | -15.10% | -1.87% | -11.34% | -1.65% |
| Operating Income | 11.81% | 9.87% | 6.63% | 8.88% | 27.89% |
| Income Before Tax | 6.26% | 26.74% | 2.17% | 5.47% | 25.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.26% | 26.74% | 2.17% | 5.47% | 25.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.26% | 26.74% | 2.17% | 5.47% | 25.98% |
| EBIT | 11.81% | 9.87% | 6.63% | 8.88% | 27.89% |
| EBITDA | 12.46% | 13.40% | 7.02% | 9.21% | 29.50% |
| EPS Basic | 6.06% | 26.88% | 2.53% | 5.26% | 25.84% |
| Normalized Basic EPS | 7.32% | 2.50% | 2.04% | 5.08% | 26.79% |
| EPS Diluted | 6.06% | 26.88% | 2.53% | 5.26% | 25.84% |
| Normalized Diluted EPS | 7.32% | 2.50% | 2.04% | 5.08% | 26.79% |
| Average Basic Shares Outstanding | 0.00% | 0.28% | 0.45% | 0.45% | 0.45% |
| Average Diluted Shares Outstanding | 0.00% | 0.28% | 0.45% | 0.45% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
